Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2003;92:676-682
Published online before print March 6, 2003, doi: 10.1161/01.RES.0000065167.52922.F6
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
92/6/676    most recent
01.RES.0000065167.52922.F6v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patel, H. H.
Right arrow Articles by Gross, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patel, H. H.
Right arrow Articles by Gross, G. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Cardiomyopathy
Related Collections
Right arrow Ischemic biology - basic studies
Right arrow Physiological and pathological control of gene expression
(Circulation Research. 2003;92:676.)
© 2003 American Heart Association, Inc.


Integrative Physiology

12-Lipoxygenase in Opioid-Induced Delayed Cardioprotection

Gene Array, Mass Spectrometric, and Pharmacological Analyses

Hemal H. Patel, Ryan M. Fryer, Eric R. Gross, Richard A. Bundey, Anna K. Hsu, Marilyn Isbell, Leonard O.V. Eusebi, Roderick V. Jensen, Steven R. Gullans, Paul A. Insel, Kasem Nithipatikom, Garrett J. Gross

From the Medical College of Wisconsin, Department of Pharmacology and Toxicology, Milwaukee (H.H.P., E.R.G., A.K.H., M.I., K.N., G.J.G.); Brigham and Women’s Hospital/Harvard Medical School, Center for Neurological Diseases, Cambridge, Mass (R.M.F., S.R.G.); Wesleyan University, Department of Physics, Middletown, Conn (L.O.V.E., R.V.J.); and the University of California, San Diego, Department of Pharmacology, La Jolla (H.H.P., R.A.B., P.A.I.).

Correspondence to Garrett J. Gross, PhD, Medical College of Wisconsin, Department of Pharmacology and Toxicology, 8701 Watertown Plank Rd, Milwaukee, WI 53226. E-mail ggross{at}mcw.edu

12-Lipoxygenase (12-LO) has been shown to be a factor in acute ischemic preconditioning (IPC) in the isolated rat heart; however, no studies have been reported in delayed PC. We characterized the role of 12-LO in an intact rat model of delayed PC induced by a {delta}-opioid agonist SNC-121 (SNC). Rats were pretreated with SNC and allowed to recover for 24 hours. They were then treated with either baicalein or phenidone, 2 selective 12-LO inhibitors. In addition, SNC-pretreated rats had plasma samples isolated at different times after ischemia-reperfusion for liquid chromatographic–mass spectrometric analysis of the major metabolic product of 12-LO, 12-HETE. Similar studies were conducted with inhibitors. Gene array data showed a significant induction of 12-LO message (P<0.05) after opioid pretreatment. This induction in 12-LO mRNA was confirmed by real-time polymerase chain reaction, and 12-LO protein expression was enhanced by SNC pretreatment at 24 hours relative to vehicle treatment. Both baicalein and phenidone attenuated the protective effects of SNC pretreatment on infarct size (50±4% and 42±3% versus 29±2%, P<0.05, respectively). No significant differences were observed in 12-HETE concentrations between baseline control and SNC-treated rats. However, 12-HETE concentrations were increased significantly at both 15 minutes during ischemia and at 1 hour of reperfusion in the SNC-treated rats compared with controls. Baicalein and phenidone attenuated the increase in 12-HETE at 1 hour of reperfusion. These data suggest that SNC-121 appears to enhance message and subsequently the activity and expression of 12-LO protein during times of stress, resulting in delayed cardioprotection.


Key Words: ischemia • opioids • late phase • gene array • lipid metabolites




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
J. E. Baker, J. Su, A. Hsu, Y. Shi, M. Zhao, J. L. Strande, X. Fu, H. Xu, A. Eis, R. Komorowski, et al.
Human thrombopoietin reduces myocardial infarct size, apoptosis, and stunning following ischaemia/reperfusion in rats
Cardiovasc Res, January 1, 2008; 77(1): 44 - 53.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
C. K. Yu, Y.-H. Li, G. T. C. Wong, T. M. Wong, and M. G. Irwin
Remifentanil preconditioning confers delayed cardioprotection in the rat
Br. J. Anaesth., November 1, 2007; 99(5): 632 - 638.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. M. Tsutsumi, H. H. Patel, D. Huang, and D. M. Roth
Role of 12-lipoxygenase in volatile anesthetic-induced delayed preconditioning in mice
Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H979 - H983.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. K. Das and N. Maulik
Cardiac genomic response following preconditioning stimulus
Cardiovasc Res, May 1, 2006; 70(2): 254 - 263.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
J. Frassdorf, N. C. Weber, D. Obal, O. Toma, J. Mullenheim, G. Kojda, B. Preckel, and W. Schlack
Morphine Induces Late Cardioprotection in Rat Hearts In Vivo: The Involvement of Opioid Receptors and Nuclear Transcription Factor {kappa}B
Anesth. Analg., October 1, 2005; 101(4): 934 - 941.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
G. J. Gross, J. R. Falck, E. R. Gross, M. Isbell, J. Moore, and K. Nithipatikom
Cytochrome P450 and arachidonic acid metabolites: Role in myocardial ischemia/reperfusion injury revisited
Cardiovasc Res, October 1, 2005; 68(1): 18 - 25.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
B. L. F. Kaplan, Y. Ouyang, C. E. Rockwell, G. K. Rao, and N. E. Kaminski
2-Arachidonoyl-glycerol suppresses interferon-{gamma} production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2
J. Leukoc. Biol., June 1, 2005; 77(6): 966 - 974.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
E. R. Gross, J. N. Peart, A. K. Hsu, J. A. Auchampach, and G. J. Gross
Extending the cardioprotective window using a novel {delta}-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway
Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2744 - H2749.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
X. Jiang, E. Shi, Y. Nakajima, S. Sato, K. Ohno, and H. Yue
Cyclooxygenase-1 Mediates the Final Stage of Morphine-Induced Delayed Cardioprotection in Concert With Cyclooxygenase-2
J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1707 - 1715.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. E. Rockwell and N. E. Kaminski
A Cyclooxygenase Metabolite of Anandamide Causes Inhibition of Interleukin-2 Secretion in Murine Splenocytes
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 683 - 690.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
A. B. Stein, X.-L. Tang, Y. Guo, Y.-T. Xuan, B. Dawn, and R. Bolli
Delayed Adaptation of the Heart to Stress: Late Preconditioning
Stroke, November 1, 2004; 35(11_suppl_1): 2676 - 2679.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. R. Gross, A. K. Hsu, and G. J. Gross
Acute Aspirin Treatment Abolishes, whereas Acute Ibuprofen Treatment Enhances Morphine-Induced Cardioprotection: Role of 12-Lipoxygenase
J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 185 - 191.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
E. Murphy
Primary and Secondary Signaling Pathways in Early Preconditioning That Converge on the Mitochondria to Produce Cardioprotection
Circ. Res., January 9, 2004; 94(1): 7 - 16.
[Abstract] [Full Text] [PDF]